These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 20466624)
21. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894 [TBL] [Abstract][Full Text] [Related]
22. [Monoclonal antibody therapy for non-Hodgkin's lymphoma]. Paul F; Rossi JF; Cartron G Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313 [TBL] [Abstract][Full Text] [Related]
23. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case]. Chen DB; Wang Y; Shen DH Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597 [No Abstract] [Full Text] [Related]
24. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. Keilholz U; Szelényi H; Siehl J; Foss HD; Knauf W; Thiel E Leuk Lymphoma; 1999 Nov; 35(5-6):641-2. PubMed ID: 10609806 [No Abstract] [Full Text] [Related]
25. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Boye J; Elter T; Engert A Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096 [TBL] [Abstract][Full Text] [Related]
26. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142 [TBL] [Abstract][Full Text] [Related]